Last Updated : April 28, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area Sort descending | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Eliquis | Apixaban | Thromboembolic events prevention, (atrial fibrillation) | List with clinical criteria and/or conditions | Complete | ||
| Pradaxa | Dabigatran etexilate | Thromboembolism (venous), prevention | Do not list | Complete | ||
| Xarelto | Rivaroxaban | Thromboembolism (venous), prevention | List with clinical criteria and/or conditions | Complete | ||
| Retevmo | selpercatinib | Thyroid cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
| Retevmo | selpercatinib | Thyroid cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
| TBC | exagamglogene autotemcel | Transfusion-dependent β-thalassemia | Pending | |||
| Ferriprox | deferiprone | Transfusional iron overload | Reimburse with clinical criteria and/or conditions | Complete | ||
| Ferriprox | Deferiprone | Transfusional iron overload | List with clinical criteria and/or conditions | Complete | ||
| Vyndaqel | tafamidis | transthyretin-mediated amyloidosis | Reimburse with clinical criteria and/or conditions | Complete | ||
| Vyndaqel | tafamidis | Transthyretin-mediated amyloidosis | Reimburse with clinical criteria and/or conditions | Complete |
Last Updated : April 28, 2024